- Home
- HPQ vs GH Comparison
HPQ vs GH Comparison
Compare HPQ & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPQ | GH |
|---|---|---|
| Founded | 1939 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 22.9B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HPQ | GH |
|---|---|---|
| Price | $29.35 | $153.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 26 |
| Target Price | $27.44 | ★ $200.76 |
| AVG Volume (30 Days) | ★ 12.7M | 2.2M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $55,295,000,000.00 | $982,021,000.00 |
| Revenue This Year | $8.13 | $39.14 |
| Revenue Next Year | $0.75 | $35.11 |
| P/E Ratio | $16.20 | ★ N/A |
| Revenue Growth | 3.24 | ★ 32.88 |
| 52 Week Low | $17.56 | $74.55 |
| 52 Week High | $36.23 | $191.05 |
Technical Indicators
Market Signals| Indicator | HPQ | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 39.49 |
| Support Level | $26.84 | $138.64 |
| Resistance Level | $29.65 | $177.55 |
| Average True Range (ATR) | 1.35 | 10.13 |
| MACD | -0.13 | -1.95 |
| Stochastic Oscillator | 32.31 | 33.14 |
Price Performance
Historical ComparisonAbout HPQ HP Inc.
HP is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one-third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.